Newsroom | 38307 results

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), (“Organon” o “la Società”) azienda sanitaria globale con la missione di offrire medicine e soluzioni ad alto impatto per migliorare la salute di tutti i giorni, ha annunciato oggi la firma di un accordo con Laborie Medical Technologies Corp. (“Laborie”), azienda leader nella tecnologia medica terapeutica e diagnostica, per l'acquisto del JADA System. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the Company has agreed with Alcon Inc. (SIX/NYSE: ALC) to amend their merger agreement to allow proactive solicitation by STAAR of third-party proposals to maximize value for all STAAR stockholders. The amended agreement includes: A new 30-day go-shop period: The new go-shop period...

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC) (“ATEC”), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced with great sadness that Jeffrey P. Rydin, a valued member of its Board of Directors, has passed away at age 59, following a lengthy illness. Mr. Rydin enjoyed nearly three decades of experience in the medical device and healthcare industries, including senior sales leadership roles at Ellipse Technologi...

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies 2025 London Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, November 19, 2025 at 8:30 a.m. GMT. A live webcast of the...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie...

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) ("Novanta" or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has priced its previously announced public offering of 11 million of its 6.50% tangible equity units at $50.00 per unit (equal to the stated amount per unit). The transaction is a public offering made by means of a prospectus supplement under Novanta’s effective shelf registration statement. Novanta’s...

美國紐澤西州普林斯頓市--(BUSINESS WIRE)--(美國商業資訊)-- NJ Bio，股份有限公司，一家位於新澤西州普林斯頓的主要契约研究和臨床製造服務提供者，宣佈購買資產並全面整合L2P研究實驗室的研究服務® （“實驗室到藥房”），進一步擴大其服務組合，助力彌合轉化研究領域的鴻溝。 現時，通過1期臨床試驗的生物分子的磨損率非常高，克服這一挑戰的方法是通過轉化研究。 NJ Bio專注於臨床前和早期臨床研究和開發，主要關注ADC、生物偶聯、定制合成、寡核苷酸和mRNAs。 然而，公司此前在向客戶提供系統化轉化研究服務方面仍存在缺口。 通過資產購買和L2P服務的綜合，NJ Bio現在可以在一個傘下提供一套全面的臨床前和轉化研究服務，並將項目從概念驗證無縫地轉移到臨床。 這種方法支持更智慧的數據驅動決策，加快開發進度，改善臨床結果，為客戶的1期及以後項目提供更好的成功機會。 L2P研究實驗室® 其綜合臨床前研發支持，特別是在腫瘤學研究和支持IND應用的服務方面，得到了廣泛認可。 隨著這些服務綜合到NJ Bio的產品中，L2P研究實驗室® , 已停止獨立運營，其臨床前和轉化研究服務組...

RALEIGH, Carolina do Norte--(BUSINESS WIRE)--A Merz Aesthetics, a maior empresa do mundo dedicada à estética médica, anunciou hoje a aprovação do Ultherapy PRIME pela Food and Drug Administration (FDA) dos EUA para melhorar a aparência da flacidez da pele na parte anterior e posterior dos braços e no abdômen. O Ultherapy PRIME é a única solução aprovada pela FDA com visualização em tempo real para tratar o rosto**, pescoço, colo e agora o corpo*.1 As novas indicações serão lançadas nos EUA ante...

RALEIGH, Carolina del Norte--(BUSINESS WIRE)--Merz Aesthetics, la empresa dedicada a la estética médica más grande del mundo, anunció hoy que la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos aprobó Ultherapy PRIME para mejorar la apariencia de la flacidez cutánea en la parte anterior y posterior de los brazos y en el abdomen. Ultherapy PRIME es la única solución aprobada por la FDA con visualización en tiempo real para tratar el rostro**, el cuello, el escote y ahora ta...

美国新泽西州普林斯顿--(BUSINESS WIRE)--(美国商业资讯)-- 位于新泽西州普林斯顿的领先合同研究与临床生产服务提供商NJ Bio, Inc.宣布已完成对L2P Research Labs®（“Lab to Pharmacy”） 研究服务资产的收购与全面整合。此次收购将进一步丰富NJ Bio的服务组合，助力弥合转化研究领域的鸿沟。 目前，生物分子在通过I期临床试验后的流失率依然居高不下，而要应对这一挑战，强化转化研究至关重要。NJ Bio长期专注于临床前及早期临床研发，重点领域涵盖抗体偶联药物（ADCs）、生物偶联、定制合成、寡核苷酸及信使RNA（mRNA）等。然而，公司此前在向客户提供系统化转化研究服务方面仍存在缺口。通过此次对L2P服务的资产收购与整合，NJ Bio现已能够在同一平台下提供完整的临床前与转化研究一体化服务，使研发项目得以顺畅衔接，从概念验证阶段无缝推进至临床试验。此举不仅支持更智能、数据驱动的决策，加速研发进程，提升临床成果，还将显著增强客户I期及后续研发项目的成功率。 L2P Research Labs®以其一体化的临床前研发支持能力享有盛誉，尤其...